Press release
Regeneron Reports Second Quarter 2023 Financial and Operating Results
Second quarter 2023 revenues increased 11% to $3.16 billion versus second quarter 2022Second quarter 2023 Dupixent® global net sales (recorded by Sanofi)
About this update from Regeneron Pharmaceuticals, Inc.
[{"type":"text","content":"Second quarter 2023 revenues increased 11% to $3.16 billion versus second quarter 2022Second quarter 2023 Dupixent® global net sales (recorded by Sanofi) increased 33% to $2.79 billion versus second quarter 2022Second quarter 2023 EYLEA® U.S. net sales were $1.50 billionSecond quarter 2023 GAAP diluted EPS of $8.50 and non-GAAP diluted EPS(a) of $10.24Two-year results reported for aflibercept 8 mg from pivotal PHOTON trial demonstrated durable vision gains at extended dosing intervals in diabetic macular edema (DME)Aflibercept 8 mg BLA decision anticipated in third quarter 2023 TARRYTOWN, N.Y., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2023 and provided a business update. \"Regeneron delivered strong financial results in the second quarter of 2023 through increasingly diversified revenue streams, and we remain well-positioned for long-term growth,\" said Leonard S. Schleifer, M.D., Ph.D., Board Co-Chair, President and Chief Executive Officer of Regeneron. \"In the past months, we have continued to advance our pipeline, in particular aflibercept 8 mg which we are progressing towards a potential FDA decision in the third quarter and for which we shared unprecedented two-year results in the pivotal PHOTON trial demonstrating durable vision gains at extended dosing intervals in patients with diabetic macular edema.\" Financial Highlights ($ in millions, except per share data) Q2 2023 Q2 2022 % ChangeTotal revenues $3,158 $2,857 11 %GAAP net income $968 $852 14 %GAAP net income per share - diluted $8.50 $7.47 14 %Non-GAAP net income(a) $1,182 $1,127 5 %Non-GAAP net income per share - diluted(a) $10.24 $9.77 5 % \"I am pleased with the performance of our business in the second quarter of 2023, including incremental pipeline progress and exceptional commercial execution,\" said Robert E. Landry, Executive Vice President, Finance and Chief Financial Officer of Regeneron. \"We continue to prioritize internal investments while allocating additional capital to opportunistic share repurchases and potential business development.\" Business Highlights Key Pipeline ProgressRegeneron has approximately 35 product candidates in clinical development, including a number of marketed products for which it is investigating additional indications. Updates...